LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Crinetics Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

32.87 2.27

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

32.05

Max

33.06

Schlüsselkennzahlen

By Trading Economics

Einkommen

-16M

-97M

Verkäufe

361K

361K

EPS

-1.04

Gewinnspanne

-26,807.202

Angestellte

437

EBITDA

-17M

-110M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+128.96% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-174M

3B

Vorheriger Eröffnungskurs

30.6

Vorheriger Schlusskurs

32.87

Nachrichtenstimmung

By Acuity

43%

57%

148 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Juni 2025, 14:31 UTC

Ergebnisse

New York State Retirement Fund Posts 5.84% Annual Investment Return

6. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Juni 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. Juni 2025, 20:33 UTC

Ergebnisse

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. Juni 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6. Juni 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6. Juni 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6. Juni 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6. Juni 2025, 16:35 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. Juni 2025, 16:34 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. Juni 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. Juni 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Juni 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Juni 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6. Juni 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6. Juni 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6. Juni 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6. Juni 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Juni 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6. Juni 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6. Juni 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6. Juni 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6. Juni 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6. Juni 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Juni 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6. Juni 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6. Juni 2025, 14:12 UTC

Ergebnisse

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6. Juni 2025, 14:09 UTC

Ergebnisse

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Peer-Vergleich

Kursveränderung

Crinetics Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

128.96% Vorteil

12-Monats-Prognose

Durchschnitt 74 USD  128.96%

Hoch 97 USD

Tief 53 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Crinetics Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

8

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

30.39 / 33.46Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

148 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.